Ajanta Pharma Launches Met-XL D to Improve Outcomes for Heart Failure and Post-Myocardial Infarction Patients

The American College of Cardiology guidelines mention a Class 1a recommendation for beta-blockers and SGLT2 inhibitors in heart failure with reduced ejection fraction (HFrEF) to reduce mortality and hospitalizations. The European Society of Cardiology guidelines suggest a Class 1a recommendation for SGLT2 inhibitors and a Class 2b recommendation for beta-blockers in heart failure with mildly reduced ejection fraction (HFmrEF).

With 24-hour blood pressure control and reduced pill burden, this combination therapy is designed to improve the clinical status, functional capacity, and quality of life among heart failure patients.

Speaking to Medical Dialogues Mr. Pourus Vakil, President & India Business Head, from Ajanta Pharma said "At Ajanta Pharma, we are committed to advancing cardiovascular disease care through innovative therapeutic solutions. The dual action of metoprolol and dapagliflozin provides comprehensive care, reducing hospitalization, improving heart function and ultimately saving lives. Aligned with the latest clinical guidelines, we aim to improve clinical outcomes and quality of life in high-risk patients."

Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by Alkem labs.